Novartis

Global pharmaceutical company applying AI to drug discovery through collaborations with Isomorphic Labs and Dyno Therapeutics.

AI Partnerships & Deployments

2025-02-18 — Expansion of the Isomorphic Labs collaboration (Isomorphic Labs). Novartis and Isomorphic Labs expanded their existing drug-design collaboration to add three additional research programs. No separate financial figure was disclosed for the expansion. Source: PR Newswire (Isomorphic Labs release) (accessed 2026-07-29)
2024-01-07 — Strategic AI drug discovery collaboration with Isomorphic Labs (Isomorphic Labs). Multi-target research collaboration applying Isomorphic Labs' AI drug-design engine to discover small-molecule therapies against three undisclosed targets. Novartis paid $37.5 million upfront, with Isomorphic eligible for up to $1.2 billion in milestone payments plus royalties. Disclosed: $37.5M upfront; up to $1.2B in milestones. Source: PR Newswire (Isomorphic Labs release) (accessed 2026-07-29)
2020-05-11 — Ocular AAV gene-therapy vector collaboration with Dyno Therapeutics (Dyno Therapeutics). Collaboration using Dyno Therapeutics' AI-powered CapsidMap platform to design novel adeno-associated virus (AAV) vectors for ocular gene therapies. No financial terms were publicly disclosed. Source: Business Wire (Dyno Therapeutics release) (accessed 2026-07-29)